Empowering Individuals, Organizations, and Healthcare Providers Since 2019
As interest grows in the effects of GLP-1based therapies beyond diabetes and obesity, questions are emerging about their potential impact on migraine
Second and third gener ation cephalosporins (e.g
A phase III trial (NCT02017340) testing the efficacy and safety of nilvadipine ( 29 ) in participants with mild to moderate AD indicated that, while the drug demonstrated good safety, it did not show significant benefits in slowing cognitive decline in AD patients
7, 2025 The 1 Thing You Shouldnt Let Hold You Back from Making Your Dreams Become Real Getting the timing right for cosmetic surgery is already difficult, between taking time off and getting help with kids or covering daily responsibilities
The results were consistent: Trunk fat reduction: Tesamorelin-treated patients showed statistically significant reductions in trunk fat versus placebo at 26 weeks.[1] VAT reduction: Using cross-sectional CT imaging, tesamorelin produced approximately 1520% reductions in visceral adipose tissue compared to placebo.[1,2] Triglyceride improvement: Alongside fat reduction, tesamorelin improved triglyceride levels a key marker in metabolic syndrome.[2] Tesamorelin IGF-1 elevation: Treatment reliably elevated IGF-1 levels toward age-appropriate norms, confirming successful GH-axis stimulation.[1] These reductions occurred without dietary caloric restriction being mandated
